Inovio Pharmaceuticals, Inc. (LON:0A43)

Market Cap	81.07M +27.5%
Revenue (ttm)	135.65K -10.4%
Net Income	-80.41M
EPS	-2.07
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	17,131
Average Volume	14,510
Open	1.680
Previous Close	1.739
Day's Range	1.569 - 1.710
52-Week Range	1.300 - 2.970
Beta	1.63
RSI	44.48
Earnings Date	Feb 27, 2026

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervi...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1983
• Employees: 134
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0A43

Financial Performance

In 2024, Inovio Pharmaceuticals's revenue was $217,756, a decrease of -73.83% compared to the previous year's $832,010. Losses were -$107.25 million, -20.62% less than in 2023.

Financial numbers in USD